



29 May 2020

Acrux announces marketing and distribution agreement with TruPharma LLC

Melbourne, Australia; 29 May 2020: Acrux Limited (ASX:ACR) (“**Acrux**” or the “**Company**”) is pleased to announce that its 100% owned subsidiary Acrux DDS Pty Ltd has entered into an exclusive sales, marketing and distribution agreement with TruPharma, LLC (“**TruPharma**”) in the United States (“**Agreement**”).

Subject to approval by the US Food and Drug Administration (“FDA”) TruPharma will be responsible for the commercialisation of 6 existing products from the Acrux pipeline, including the sponsorship and management of each FDA application, management of commercial manufacturing, marketing and distribution of each product.

The selected products are at various stages of development and have not been lodged with the FDA. Under the terms of the Agreement, Acrux will continue to conduct the development, scientific and bioequivalence activities necessary to develop the generic products and seek regulatory approval with the FDA.

Acrux and TruPharma will share the gross profits generated from the sales of the generic products.

The Agreement for each product will have a 10-year term from launch, unless otherwise agreed.

Acrux CEO and Managing Director, Michael Kotsanis said:

“We are excited to enter into this agreement with TruPharma and we look forward to developing a long-lasting relationship between the two companies. The agreement marks a significant step forward in achieving Acrux’s transition into the generics market.”

Authorised by the Board of Acrux Limited.

For more information, please contact:

General enquiries

Michael Kotsanis

Acrux Limited

CEO & Managing Director

P: + 61 3 8379 0100

E: michael.kotsanis@acrux.com.au



About Acrux

Acrux (ASX: ACR) is a pharmaceutical company dedicated to developing and commercialising topical pharmaceuticals. Incorporated in 1998 and using in house facilities and capabilities, Acrux has successfully developed and commercialised through licensees a number of topically applied pharmaceutical products in the US and Europe. Acrux is developing of a range of generic products for the US market by leveraging its on-site laboratories, GMP manufacturing suite, clinical and commercial experience to bring affordable products to market. Acrux encourages collaboration and is well positioned to discuss partnering and product development.

For further information on Acrux, visit www.acrux.com.au

About TruPharma

TruPharma (private) is a company focused on sales, marketing, and distribution of high-quality prescription pharmaceutical products in the U.S. market. TruPharma partners with skilled developers and reliable manufactures to bring niche and limited supply products to its customers. TruPharma is owned and operated by seasoned executives with extensive experience overcoming legal and regulatory hurdles to FDA approvals, and selling products to all classes of trade. TruPharma's independence and experience has made it a front-end partner of choice for companies targeting the US pharmaceutical market.

For further information on TruPharma, visit www.trupharma.com